Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.50 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.49 |
| ▸ | KRAS | P01116 | 7/20 | 0.47 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19822457 | 1.00 | NT5E (0.54) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL22224707 | 0.94 | TGM2 (0.56) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL22224710 | 0.93 | TGM2 (0.55) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL16023834 | 0.93 | TGM2 (0.55) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL12151899 | 0.93 | TGM2 (0.55) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL12150020 | 0.93 | TGM2 (0.55) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL1376829 | 0.89 | NT5E (0.48) | NT5EPOLBTGM2KRASFUT5 | |
| SCHEMBL15045985 | 0.89 | HINT1 (0.48) | NT5EPOLBTGM2TAS1R3TAS1R1 | |
| SCHEMBL4409827 | 0.88 | NT5E (0.57) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL15045974 | 0.87 | HINT1 (0.49) | NT5EPOLBTGM2FUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017958-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3865136-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR CORONA VIRUS TREATMENT | ATEA Pharmaceuticals, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| US-10946033-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | Atea Pharmaceuticals, Inc. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200222442-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2020-07-16 | — | — | US | disclosed |
| US-20190201433-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222442-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | NSUN2, ADAR, NSUN3 | NT5E 92/4885POLB 330/4885IMPDH2 150/4885 |
| US-10946033-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | NSUN2, ADAR, NSUN3 | NT5E 90/4885POLB 333/4885IMPDH2 152/4885 |
| US-20190201433-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | NSUN2, ADAR, NSUN3 | NT5E 92/4885POLB 330/4885IMPDH2 150/4885 |
| US-20230017958-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | NSUN2, ADAR, NSUN3 | NT5E 92/4885POLB 330/4885IMPDH2 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.